Patents by Inventor Sherven Sharma
Sherven Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793860Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: August 12, 2020Date of Patent: October 24, 2023Assignees: The Regents of the University of California, The United States Government as Represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie Ann Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Publication number: 20220162279Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors. Exemplary checkpoint molecules include CTLA-4, a CTLA-4 receptor, PD-1, PD1-L1, PD1-L2, 4-1BB, OX40, LAG-3, TIM-3 or a combination thereof. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: ApplicationFiled: January 18, 2022Publication date: May 26, 2022Applicants: The Regents of the University of California, United States Government represented by the Department of Veterans AffairsInventors: Steven M. DUBINETT, Sherven SHARMA, Jay M. LEE
-
Patent number: 11236139Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors. Exemplary checkpoint molecules include CTLA-4, a CTLA-4 receptor, PD-1, PD1-L1, PD1-L2, 4-1BB, OX40, LAG-3, TIM-3 or a combination thereof. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: GrantFiled: November 5, 2015Date of Patent: February 1, 2022Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Steven M. Dubinett, Sherven Sharma, Jay M. Lee
-
Publication number: 20200368319Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: ApplicationFiled: August 12, 2020Publication date: November 26, 2020Inventors: Leonard H. Rome, Valerie Ann Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 10780147Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: February 3, 2017Date of Patent: September 22, 2020Assignees: The Regents of the University of California, The United States Government as Represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 10166277Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.Type: GrantFiled: September 5, 2016Date of Patent: January 1, 2019Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Sherven Sharma, Steven M. Dubinett, Isaac Yang, Linda M. Liau, Kathleen A. Kelly, Jian Yang, Upendra K. Kar, Cheryl Champion, Janina Jiang
-
Publication number: 20180194825Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors. Exemplary checkpoint molecules include CTLA-4, a CTLA-4 receptor, PD-1, PD1-L1, PD1-L2, 4-1BB, OX40, LAG-3, TIM-3 or a combination thereof. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: ApplicationFiled: November 5, 2015Publication date: July 12, 2018Inventors: Steven M. Dubinett, Sherven Sharma, Jay M. Lee
-
Publication number: 20170143797Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: ApplicationFiled: February 3, 2017Publication date: May 25, 2017Applicants: The Regents of the University of California, The United States Government as represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Ph.D., Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 9597372Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: November 25, 2014Date of Patent: March 21, 2017Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Publication number: 20160367653Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.Type: ApplicationFiled: September 5, 2016Publication date: December 22, 2016Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Sherven Sharma, Steven M. Dubinett, Isaac Yang, Linda M. Liau, Kathleen A. Kelly, Jian Yang, Upendra K. Kar, Cheryl Champion, Janina Jiang
-
Publication number: 20160058837Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: ApplicationFiled: March 31, 2015Publication date: March 3, 2016Applicants: The Regents of the University of California, The Department of Veterans' AffairsInventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj Batra
-
Publication number: 20150150821Abstract: The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.Type: ApplicationFiled: July 9, 2013Publication date: June 4, 2015Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Sherven Sharma, Steven M. Dubinett, Isaac Yang, Linda M. Liau, Kathleen A. Kelly, Jian Yang, Upendra K. Kar, Cheryl Champion, Janina Jiang
-
Publication number: 20150150944Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: ApplicationFiled: November 25, 2014Publication date: June 4, 2015Applicants: The Regents of the University of California, The United States Government Represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Patent number: 8920807Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: GrantFiled: November 2, 2010Date of Patent: December 30, 2014Assignees: The Regents of the University of California, The United States of America Represented by the Department of Veterans AffairsInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Publication number: 20120213809Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.Type: ApplicationFiled: November 2, 2010Publication date: August 23, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
-
Publication number: 20040175355Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: ApplicationFiled: January 13, 2004Publication date: September 9, 2004Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj K. Batra
-
Publication number: 20030175801Abstract: The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids.Type: ApplicationFiled: April 18, 2002Publication date: September 18, 2003Inventors: Steven M. Dubinett, Robert M. Strieter, Sherven Sharma, Raj K. Batra